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Nanomedicine as a translational science has the goal to provide cost ef-
fective novel therapies and diagnostics using the expanding world of Nano-
technology. To reach this goal the process of translating research results from 
labs to the clinic has to be greatly improved. 
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What if doctors could search out and destroy the very first cancer cells 
that would otherwise have caused a tumour to develop in the body? [...] 
What if pumps the size of molecules could be implanted to deliver life-saving 
medicines precisely when and where they are needed? 
These scenarios may sound unbelievable, but they are the long-term 
goals of the Nih Roadmap's Nanomedicine initiative that we anticipate will 
yield medical benefits as early as 10 years from now. 
Nih Roadmap for Medical Research  
These brief, but sharp, quotations, drawn up by two major regulatory 
and investment authorities in the field of nanomedicine1, clearly describe 
the potential implications of the ‘infinitely small’ for translational research 
in life sciences. Nanotechnologies appear to be capable of improving 
knowledge translation between scientific laboratories and clinical settings, 
and a number of new treatments and refined diagnostic tools are ex-
pected in the very near future.  
In recent years, the scientific movement of nanomedicine, which 
emerged under the aegis of translational research, exemplifying the con-
nection between scientific research and patient care, has become fairly 
significant in the field of post-genomic sciences (Baird et al. 2004; Tsai-
hsuan Ku 2012). The proponents of translational research in nanomedi-
cine believe that, within a relatively short time, a new set of ‘smart’ thera-
peutic tools incorporating a variety of functions, such as the controlled 
release and ‘real-time’ quantification of drugs, will soon be available to 
doctors and patients, enabling adaptation of therapies to the genetic pe-
culiarities of individuals (Venugopal et al. 2008; Tibbals 2011).  
Nanomedicine is now being promoted as a potential driver of biomed-
ical innovation, capable of opening a therapeutic scenario in which treat-
ments will become personalised, and individuals will take an increasingly 
active role in the control and maintenance of their daily well-being. In 
this sense, the standard view of nanomedicine, supported by the biomed-
ical community and circulating in major scientific journals, appears to be 
characterised by a ‘future-oriented debate’ that is to be understood as the 
complex ‘outcome’ of scientific narrations, expectations, anticipations 
and future visions arising from the potential application of nanotechnolo-
gy in the context of patient care (Grunwald 2004; Lösch 2006; Ach and 
Lüttenberg 2008).  
The ongoing dialogue between nanotechnology and biotechnology is a 
topic of undoubted importance for Science and Technology Studies 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 The first excerpt was written by a team of experts from the European Technology 
Platforms on Nanomedicine (Etpn). Etpn is an initiative promoted by the Europe-
an Commission, together with a strategic alliance of private enterprises, with the 
aim of pursuing the application of nanotechnology within medical and clinical 
contexts. The second quotation, appearing in Tibbals (2011), was taken from 
Nih's Roadmap Nanomedicine Initiative, which is a platform founded and fi-
nanced by the National Institutes of Health of the United States. 
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(STS). In the last decade, numerous contributions within STS have shed 
light on the ways in which anticipatory expectations and “forward-
looking statements” (Fortun 2002) concerning scientific and technologi-
cal progress may be regarded as rhetorical devices capable of attracting 
the attention of relevant stakeholders, such as policymakers, investors and 
directors of research laboratories, together with a number of financial, 
regulatory and symbolic resources (Brown et al. 2000; Holtzman and 
Marteau 2000; Levidow and Marris 2001; Sturken et al. 2004). In this 
florid debate, one of the most recent developments has been the growing 
interest in how real-time practices are performed in relation to future-
oriented scientific narrations (Borup et al. 2006; Horst 2007).  
Starting from these theoretical suggestions, and based on the data col-
lected during an ethnographic research conducted in a laboratory of na-
nomedicine based in Northern Italy and operating in the field of 
experimental and clinical pharmacology, I explore in detail the relation-
ship between anticipatory knowledge, scientific forward-looking state-
ments and the situated practices of biomedical research in nanomedicine. 
In particular, I focus on the processual dimension of scientific narrations 
on nanomedicine, in order to understand how future-oriented abstrac-
tions may represent a fundamental element for the local practices of na-
nomedical research. In doing so, and referring in particular to a socio-
technical artifact called “triangle Dna origami”, I develop the notion 
of promissory bio-object as a conceptual device to enable improved under-




2. Theoretical Tributaries 
 
Anticipatory narrations and expectations regarding science and tech-
nology always involve a set of linguistic statements on particular events 
located within a future-oriented imaginary world, which is still incom-
plete, but likely to come into effect in certain circumstances (Adam and 
Groves 2007). Nanomedicine and translational research in general are 
permeated by rumours and debates outlining future life technologies, fu-
ture benefits, future patients and future clinical applications (Ioannidis 
2004; Thacker 2004; Martin et al. 2006; Wainwright et al. 2006; Selin 
2007).  
In accordance with the lively debate on the relationship between an-
ticipatory narrations and technoscientific innovation, the last decade saw 
the establishment of the so-called “sociology of technoscientific expecta-
tions” (Brown and Michael 2003). This approach has been used to inves-
tigate the way in which expectations, promises and visions, by means of 
cultural metaphors, narrative scripts or forecasting policies (Michael 
2000; Wyatt 2000; Király et al. 2013), are projected and manipulated in 
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the public sphere as a resource for driving research and development ac-
tivities and change in the present (Rosenberg 1976; Van Lente 1993; Van 
Lente and Rip 1998; Brown et al. 2000).  
In this theoretical framework, the emergence of post-genomic 
nano/biotechnologies has been interpreted as part of the construction of 
a new bio-technoscientific regimen, where it may find a number of cul-
tural expectations, biomedical scenarios and promises relating to the po-
tential revolutionary benefits of new treatments or diagnostic and clinical 
practices (Selin 2006; Hedgecoe and Martin 2007; den Boer et al. 2009; 
Rose and Rose, 2012; Groves 2013). Research has focused on the im-
portance of expectations for the emergence of innovative biomedical 
fields, such as genomics and biotechnology (Fleising 2001; Fortun 2001, 
2002), pharmacogenomics (Hedgecoe and Martin, 2003; Hedgecoe 
2006), telemedicine (Rappert and Brown 2000) and information technol-
ogy (Geels and Smit 2000; Wyatt 2000; Casper 2005). From an analytical 
perspective, the above contributions have led to a ‘top-down’ mapping of 
anticipatory narrations. In particular, the authors have addressed only the 
temporal cycles of emergence and partial disappearance of anticipatory 
rhetoric in public spaces, mainstream media or scientific journals.  
In this sense, the close relationship between forward-looking state-
ments and the local articulations of scientific research has been neglected. 
As a consequence, the importance of investigating the way in which scien-
tific expectations of the “future of nanomedicine” may take on a material 
dimension, becoming variously incorporated into diagnostic procedures, 
treatment options, and new biomedical technologies, strikingly emerges.  
In order to address this issue, it is useful to look at those debates 
which, focusing on the sociomaterial dimension of technoscientific prac-
tices (Law 1987, 1994, 1999; Mol and Law 2002; Orlikowski 2007), sug-
gest that we should pay particular attention to the alignment between 
human actors, technical objects and discursive representations (Collins 
and Yearly 1992; Fujimura 1995; Suchman 2000). 
Some authors, inspired by these contributions, have recently proposed 
the notion of bio-objects, in order to conceptualise how new forms of life 
are designed and materialised into clinically actionable devices (Webster 
2011). Such a concept is useful for studying the sociomaterial process by 
which new biological entities (such as stem cells or synthetic biologically-
based devices) are created and, at the same time, how they can shape new 
clinical, regulatory and commercial issues (Waldby 2006). From an ana-
lytical standpoint, bio-objects are embodiments of knowledge in the mak-
ing that capture the reconstruction of the boundaries between biomedical 
research and clinical needs. As a consequence, they are characterised by 
mobility across different techno-scientific domains, such as laboratories 
and clinical settings (Douglas et al. 2012). Furthermore, in a seminal pa-
per, Metzler and Webster (2011) have shown that bio-objects are mani-
festations not only of material practices, but also of hopes and 
expectations with regard to the possibility of strengthening the 
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knowledge that enhances biomedical intervention in health and illness. 
On the whole, this notion suggests an innovative connection between the 
sociology of technoscientific expectations and the sociomaterial ap-
proach, enabling investigation of the performative dimension of anticipa-
tory knowledge. 
In the following sections I will focus on the relationship between sci-
entific narrations and materiality, in order to understand how the expec-
tations of translational nanomedicine can be embedded into biomedical 
practices and materialised into nanotechnological therapeutic objects. 
Specifically, in order to show how the dialogue between research and care 
practices occurs through the mediation of scientific anticipatory narra-
tions and expectations, I will focus on a detailed analysis of the activities 
involved in the design of a nanodevice, a new biological entity which can 
be defined as a promissory bio-object.  
 
 
3. Case Study: The Birth of Onco_N@no 
 
Contemporary biomedical science is concerned with the problem of 
improving the relationship between the laboratories and the bedside. Sci-
entific discourse regarding translational research has recently gained 
growing importance in shaping imagined futures concerning the applica-
tion of laboratory research in the clinic (Ioannidis 2004). In particular, as 
an emerging bio-technoscientific field of translational research (Tsai-
hsuan Ku 2012), nanomedicine clearly reveals how scientists, doctors and 
researchers can occupy a temporality that is strongly biased towards the 
near future, through the disclosure and declaration of statements and nar-
rations that outline possible developments in biomedicine (Birch 2006).  
The articulation between bench and bedside proposed by a transla-
tional paradigm may be strongly mediated by expectations and future-
oriented scientific statements. Therefore, it becomes necessary to adopt 
an empirical gaze aimed at understanding how anticipatory scenarios in 
nanomedicine will break through the walls of research laboratories and 
contribute to the innovation of biomedical practices. In this sense, the 
expectations and scientific narrations generated by the supporters of the 
new technological paradigm in nanomedicine should be understood as 
productive resources, rather than mere representative statements, which 
allow to shape and define the conditions for the development of clinical 
technologies. 
Overall, this paper is based on broader ethnographic research that 
was conducted over a period of 5 months. The empirical material was col-
lected through documentary analysis, in-depth interviews and the ethno-
graphic observation of R&D activities within a laboratory of 
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nanomedicine called Onco_N@no2.  
Onco_N@no is a newly established laboratory, which, starting in Jan-
uary 2012, has gradually been incorporated within a larger care and re-
search institute in Northern Italy that is engaged in molecular oncology. 
Doctor Gianni, an internationally recognised oncologist, has been the di-
rector since its foundation: 
 
Nanomedicine provides one of the most exciting and promis-
ing paths of research and will help us transfer laboratory discover-
ies into hospitals – explains Gianni, who deals with translational 
medicine, the aim of which is to ensure a direct contact between 
laboratory and patient. [...] Our goal: it's real-time monitoring of 
the potential side effects of a treatment, be it traditional (chemo-
therapy) or “smart” (with monoclonal antibodies and other bio-
logics drugs). When I heard that I had been awarded the funding 
from ***, I have to admit that, after the initial excitement, I was 
actually quite scared. It was a positive concern though, which had 
to do with the responsibility of coordinating a project in which I 
strongly believe and that I have been relentlessly pursuing together 
with my colleagues. (Gianni)3 
 
Gianni's considerations reveal the complexity of what must be ac-
complished locally to articulate a manifold and composite area of re-
search.  
 
Nanomedicine, this new current, is my last challenge. What is 
nanomedicine then? For me, it means designing drugs. It means 
designing drugs in a different way, in order to make them selective 
for neoplastic cells, or developing devices that can be useful for 
treatment. (Gianni) 
 
The utterances of Onco_N@no's director move from an anticipatory 
narrative level, which includes the expectations and promises involved in 
the development of new therapeutic nanotechnologies, to the level of eve-
ryday research practices, which must be coordinated in such a way as to 
confer credibility on these expectations. These two levels are, as a whole, 
the lenses through which Gianni observes the reconfiguration of biomed-
icine in the near future. He presents a scientific vision of nanomedicine as 
a tool for the understanding and manipulation of matter, on the nanome-
ter scale, for the benefit of patients and therapeutic planning. 
During my ethnographic investigation I followed in detail the early 
stages of the commissioning of Onco_N@no, which primarily involved 
two researchers: Beppe and Martino. Beppe, with an academic back-	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 Persons and locations names are pseudonyms. 
3 Interview given by Gianni in January 2012 for a magazine edited by the institute 
that co-financed Onco_N@no. 
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ground in physics, had just returned from the United States to support 
Gianni's project, suspending his position as research assistant professor in 
the department of biology of an important science and technology insti-
tute. Beppe was then joined by Martino, a young PhD student in nano-
technology, who greatly contributed to the local translation of the 
anticipatory scenario proposed by the director of Onco_N@no. 
In what follows, my focus will be in exploring how nanomedical expecta-
tions and anticipatory knowledge, such as statements of ideas and scien-
tific facts, can be inscribed and embedded into biomedical practices and 
diagnostic and therapeutic options (Borup et al. 2006). It is a point of 
particular relevance, which helps to clarify how nanomedicine can con-
tribute to the overall definition of biomedical research in contemporary 
society, and deepen the notion of promissory bio-objects as a conceptual 
device for the analysis of the processes that confer materiality, credibility 
and strength on forward-looking statements.  
 
 
4. Exploring Nanomedicine through Expectations, Techno-
logy and Materiality  
 
Since its inception, Martino and Beppe have been engaged in the 
modelling, development and visualisation of nanodevices, which are some-
times defined as “Dna origami” (Rothemund 2006) or, more suggestively, 
as a “Trojan horse to attack cancer” (New Scientist 2012). Technically, 
Dna origami can be defined as a three-dimensional structure on the na-
noscale, the shape of which is arbitrarily decided by the human operator 
by whom it is created. The peculiarity of biochemical interactions be-
tween the molecules that make up Dna4 makes it extremely useful matter 
for the construction of new forms of life that do not exist in “nature”. 
Dna origami, developed for the first time by Paul Rothemund at the la-
boratories of the California Institute of Technology, have rapidly become 
a “promissory material” for the generation of new biomedical nanotech-
nologies that are capable of improving drug treatment or “drug deliv-
ery”5: 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4 The macromolecule of Dna consists of molecules that are called bases. The bases 
are linked together in an orderly way. This phenomenon is known as complemen-
tary base-pairing. The combination of two bases is called a “base pair” and is the 
unit of measurement used to determine the length of a Dna molecule. The princi-
ple of complementary base-pairing was first described by James D. Watson and 
Francis H. Crick in 1953. 
5 The concept of drug delivery refers to a number of approaches and technologies 
applied on the nanoscale, which are intended for the transport of pharmaceutical 
compounds to the body in order to improve the efficacy and safety of treatments 
(Wang and von Recum 2011). 
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For drug delivery you need to build an intelligent structure. 
This will give you better control as compared, for example, to tra-
ditional nanotubes. You will also need to characterise this struc-
ture. Now, Dna seems to me the most suitable material. Dna is 
subject to early deterioration. And it is toxic, but for how long? 
Probably for half an hour. Whereas nanotubes, I mean... they may 
cause apoptosis of all cells. Nanotubes are toxic, and not only for 
half an hour. (Beppe) 
 
As Beppe suggested, Onco_N@no research activities were primarily 
oriented towards the production of a Dna nanostructure that could act as 
an “intelligent vector” of a specific therapeutic molecule. The clinical ra-
tionale derives from the need to identify a number of treatment regimens 
that are less invasive for the human body and have a relatively low toxici-
ty. Since the early stages of design, Beppe has framed Dna origami within 
a purely clinical actionability (Nelson et al. 2013), expressing a number of 
therapeutic expectations (for example, the reduction of toxicity level in 
drug treatments for cancer) as forerunners of his research activities:  
 
On the basis of this research work, I can say: “Yes, I can use 
this device and I know how it behaves.” And then, I can imple-
ment my origami with respect to the clinical needs. That is, for ex-
ample, the drug delivery. Why could Dna origami be a winning 
strategy for drug delivery? Because they are biocompatible. They 
are made with the same biomolecules that you find in our bodies. 
In doing this new thing, we established a few points to follow. 
First point, we are in a research and care institute, so we have to 
do something related to cancer treatment. Second point, our direc-
tor has always been involved in experimental and clinical pharma-
cology. Thirdly, we have the patients. Therefore, cancer, patients 
and medications: these are the ingredients. (Martino) 
 
Through this discursive operation, Beppe and Martino attempted to 
establish a material-semantic link between the clinical expectations and 
research activities of Onco_N@no, turning the nanomedicine laboratory 
into an instrument at the service of the patient. In this respect, research-
ers' words are pervaded by a sense of moral responsibility, demanding the 
adoption of explicit and demonstrable procedures, peculiar to a system of 
‘scientific truth’ (Hacking 2009), in order to account for and justify the 
fact that Onco_N@no's activities move towards clinical application. It is a 
practice of accountability (Garfinkel 1967) which, in conjunction with the 
modeling, development and visualisation of Dna nanodevices, confers 
credibility on the future-oriented scientific statements that constitute the 
global field of nanomedicine.  
Moreover, it is important to underline that both quotations elucidate 
how material expectations regarding translational nanomedicine out-
comes enacted by Dna origami are partially shaped by the institutional 
setting’s vision around the potential benefit of the nanodevice. At the 
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same time, the institutional vision is co-generated by the possibility of 
successfully constructing the nanodevice as a therapeutic object. In this 
sense, the articulation between bench and bedside, strongly supported by 
the translational research paradigm, is mediated by the circulation of ex-
pectations between multiple levels and domains. 
 
 
4.1. Nanomedical Modeling: Centers of Calculation and Molecu-
lar Bio-design 
 
According to the researchers’ expectations, one of the nanodevices 
designed and developed at Onco_N@no could significantly enhance the 
efficacy and safety of a specific drug or therapeutic compound with which 
it is combined: 
 
The Dna triangle that I'm preparing, as you can see, is a simple 
structure. And it is precisely for this reason that I believe that you 
can have better control when you test it on blood and in patients. 
We need a structure that can be monitored and aggregated with a 
drug, that's all. If you create an origami that is too complex, you're 
back to square one. How do you manage to check it within the 
body? (Martino) 
 
Designing the nanodevice initially involved the graphic modelling of 
the intended structure. Martino and Beppe were oriented in the creation 
of a structure having a triangular shape, hence the name triangle Dna ori-
gami (Tdo). By reason of its alleged simplicity and graphic ‘abstemious-
ness’, as Martino explained, Tdo would allow improved control by the 
operators when used in complex biological systems, such as the human 
body. However, the question of simplicity and visual abstemiousness is 
not to be understood as a mere technical problem. Describing his Dna 
molecules in familiar terms, Martino has the ability to make the subject 
accessible and intelligible, not only for researchers and the confined 
community of nanotechnologists, but also for clinicians and non-
specialists that are simply interested in laboratory scientific activities, such 
as patients.  
While I was conducting my investigation in the laboratory, it often 
happened to see researchers from other scientific institutes in Northern 
Italy (who used to visit Onco_N@no to negotiate partnerships and col-
laborations) showing great interest, and even surprise, with respect to the 
research activities of Martino and Beppe: 
 
Martino: So, first of all, I tried to select the best software to design 
my origami. I tried a few. All of them are CAD [computer-
aided design] software and are free [...]. In the end, I found 
out that the only software I could use was this one. It is called 
NanoEngineer. In my opinion, it is the best software for this 
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application, since it also allows 3D design, whereas other soft-
ware would only support 2D design. Basically, this software al-
lows you to create your own origami.  
Engineer (guest): Can you give us an idea of how you create this 
origami? 
Martino: You need to design its structure with NanoEngineer. 
This way, you will have your assembled structure, also includ-
ing complementary sequences of DNA. Once you have drawn 
the structure and you are sure about your project, you need to 
acquire Dna fragments, mix into solution, and then you can do 
the rest, that is make your reaction. 
Engineer (guest): So you are telling us that the structure is auto-
matically generated? Do you mean that the origami is automat-
ically generated out of this indistinct mixture? 
Martino: Basically, yes. 
Engineer (guest): It is truly fascinating. It is really incredible how 
you can create the structure out of this slop. Well, considering 
that we live thanks to DNA, you can easily figure out why it 
may react like this. It is a real “wager” when you mix all these 
things together trying to achieve ordered nanostructures. It is 
something beautiful and the wager is very powerful for the 
clinic.  
 
“The wager is very powerful for the clinic”: the epilogue of this con-
versation shows how the research activities in which Martino is engaged 
require the ability to manage scientific knowledge and technologies, as 
well as expectations, in the form of the scientific wager, revolving around 
nanomedicine. From the conversation between Martino and the chemical 
engineer, we learned that the design and production of the nanodevice 
implied a composite work of digital and organic, and between clinical ex-
pectations and laboratory practices, in order to develop new treatment 
strategies.  
The modelling of Dna origami is articulated through a process of 
graphic design using an open source; computer-aided design software 
called NanoEngineer-1 (Fig. 1).  
The software used by Martino conceals a sophisticated corpus of sci-
entific knowledge in the field of molecular biology behind an extremely 
simple and intuitive user interface. NanoEngineer-1 makes it possible to 
simulate the biological process of Dna reproduction and synthesis, since 
the software developers incorporated in the application a codified and 
formalised knowledge base regarding the complementary pairing of Dna 
sub-units. This means that the operator can generate 3D images of Dna 
on a nanoscale, which is potentially achievable in the laboratory. 
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Fig. 1 – Modelling of a nanomedical device with Nano_Engineer-1 
 
However, when modelling the TDO, Martino's activity was not limited to 
the use of the software. Although it may sound like a highly technical ac-
tivity, opened by software potential in itself, the modelling required the 
juxtaposition of other handmade graphic elements, such as drawings, 
prototypes and proofs (Fig. 2a and 2b). 
These were later collated in the laboratory journal and, to some ex-
tent, they express Martino's scientific creativity, which confers shape and 
materiality on the expectations of nanomedical devices. 
Such representations, sketches and drawings, may be regarded as cen-
tral elements of mediation in building Tdo digital images, and constitute 
the space in which scientific ideas regarding the future are visually re-
fined. 
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Fig. 2a – Graphic drafts of the nano          Fig. 2b – Graphic drafts of the nano 
device             device  
  
In other words, a specific medical nanotechnology that initially es-
capes the sensitive perception, becomes present, credible and, above all, 
achievable, through laboratory practices. In this respect, the goal of the 
graphic exploration of Dna molecules is not merely theoretical, nor simp-
ly attributable to the reconfiguration of new knowledge on Dna proper-
ties on the nanoscale. Despite the fact that, to a certain extent, 
nanomedicine wishes to ascertain the implications of biological processes 
on an atomic scale, the main goal of Onco_N@no research activities is to 
make an attempt to actively manipulate organic matter for the design of 
new therapeutic strategies. 
Within this experimental frame, the computer application used by 
Martino appears to be particularly relevant. While incorporating codified 
and formalised expert knowledge, the software serves as a “centre of cal-
culation” (Latour 1986, 1987) that is standardized and shared by the in-
ternational scientific community. The standardization of modelling 
procedures conveyed by the software and the digital images produced by 
Martino can meet the approval of the reference scientific community: 
Tdo digital images do not pertain to the level of imagination, but are self-
evident scientific representations of the generative potential of Dna.  
Thanks to the knowledge base incorporated in the software and rec-
ognized by the international scientific community, the blurred and anti-
thetical boundaries between “imaginary” and “scientific” are reassembled 
within an epistemologically consolidated regime of disciplinary truth 
(Knorr-Cetina 1981). In this way, researchers have constructed a “digital 
object” (Monteiro 2010) as intermediate scientific evidence that helps to 
recompose the discursive level of future nanomedicine with that which is 
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experimental. This means that the image can also be shared, displayed, 
and potentially translated into clinical practice, conferring credibility on 
the nanomedicine scenario. 
 
 
4.2. Development and Visualization of Nanodevices: Seeing Is 
Believing 
 
As described in the previous section, the concept of Dna, which is the 
constituent material of the nanodevice, pertained to a computational rep-
resentation during the modelling phase. It was a computer-based, or in 
silico, simulation of the process of synthesis and aggregation of the sub-
units forming the Tdo. The graphic design stage was followed by the in 
vitro development of the nanodevice, in the form of a biological sample. 
The Tdo development path was articulated in a number of experimental 
activities, which required the manipulation of short sequences of Dna, the 
so-called oligonucleotides, in order to confer a biological and material 
status on digital images.  
The Dna sequences have the property to aggregate into the ordered 
and predefined structures that are called Dna origami through a bio-
chemical reaction induced by heat (annealing reaction). After designing 
the image on NanoEngineer-1, Martino had to “catalogue” the different 
Dna sequences required for the preparation of the reaction that would 
lead to the formation of the desired nanodevice. The software incorpo-
rates a dedicated tool that automatically generates a list of nucleotides 
constituting the Tdo. This list is nothing more than a long list of letters 
indicating nucleotide aggregations in the form of “GATGG” etc. (Fig. 3). 
This means that the nanodevice, following in silico simulation, is translat-
ed from a visual and graphic language (the image of the triangle) into a 
conventional and standardized alphabetic language, taking on a new in-
formational dimension. When preparing the annealing reaction, based on 
a “trial and error” approach, the researcher defines an experimental pro-
tocol providing the instructions, methods, materials and sequences of ac-
tions necessary for the in vitro development of Tdo. 
Fig. 3 – Example of nanodevice informational representation 
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The overall coordination of the reaction for assembling Dna sequences is 
particularly laborious, and recursively interweaves the subsequent activi-
ties of visualization and characterization of TDO. After completion of the 
annealing reaction, Martino obtained a set of biological samples, in which 
he may have reasonably expected aggregation of Dna sequences for gen-
eration of the nanodevice. At this point, it is necessary to adopt a number 
of experimental procedures to verify the formation of the desired 
nanostructures. This verification phase also has a characterization func-
tion, since it allows the estimation of some of the biochemical properties 
of the product obtained from the reaction. The visualization of the 
nanostructure is achieved through an experimental procedure that is fair-
ly consolidated in molecular biology laboratories: electrophoresis. This 
technique for the analysis and separation of Dna molecules enables the 
production of very particular images (Fig. 4), as well as a further graphic 
and visual representation of the nanodevice. 
 
Fig. 4 – View of the nanodevice after electrophoresis  	  
The visual representations of the nanodevice, obtained through elec-
trophoresis and subsequent exposure of Dna inside a photographic de-
vice, are configured as ‘light/dark bands’ and form visual objects of 
mediation between the computational and purely biological status of 
Tdo, achieved through experimental laboratory practice. As shown in 
figure 5, Martino is comparing the image of his nanodevice with one that 
is standard, or a molecular weight marker, in order to assess whether the 
resulting “light/dark bands” are compatible with the formation of Tdo. If 
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the evaluation of the ‘bands’ does not meet the expected outcome, the 
protocol should be reviewed, and further development and characterisa-
tion activities should be defined. 
Beyond the technical aspects, what is interesting is the use of a highly 
standardised set of technologies within an experimental process that in-
corporates a potentially high degree of innovation. Although Martino is 
engaged in an innovative, and therefore unstable and lacking in estab-
lished standard procedures, field of nanomedicine, it becomes clear how 
the production of scientific knowledge is connected not only with On-
co_N@no-situated purposes and the information obtained from the ma-
terials used, but also with a set of knowledge and practices that have been 
“inherited” from biomolecular scientific culture. In this sense, while  
 
 
Fig. 5 – Standards for the evaluation of the nanodevice 
 
identifying an ambiguous and opaque biological entity, Tdo calls for the 
alignment of a set of experimental data and scientifically established 
technologies in order to manage its controversial and “esoteric” dimen-
sion. In other words, in order to assess the outcome of the experimental 
process for the construction of the nanodevice, and determine whether it 
also has a material status, in addition to being purely discursive and in-
formational, it is necessary to identify a set of reliable procedures to allow 
its visualisation. To some extent, Martino implements an established sci-
entific repertoire within an emerging scientific field, in order to give the 
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procedures a robust epistemological status, and to naturalise a number of 
emerging scientific practices that still remain opaque and uncertain (Col-
lins 1981; Collins and Pinch 1993). 
Overall, the activities of modelling, development and visualisation of 
Tdo can be understood as explicit scientific procedures that allow the an-
choring of the debate on nanomedical future to the local biomedical set-
ting. The outcome of these activities was the production of a new 
biological entity, a bio-object, which conveys and materialises the set of 
expectations revolving around the foundation of the laboratory.  
This reflection, in accordance with other contributions, documents 
the central role of visual representation in nanomedicine research (Mes-
trutti 2011; de Ridder-Vignone and Lynch 2012). We can see how expec-
tations and scientific imaginings are turned into images as a means of 
construction and communication of objectivity (Daston and Galison 
1992, 2007). In particular, the graphic representations of the Tdo enable 
an important dimension of the scientific images that Burri called visual 
persuasiveness (Burri 2012, 53). This visual dimension emphasises the rel-
evance of images as scientific evidence that make visible the natural world 
(Frow 2012); or rather, in being considered objective and true, as an em-
anation of the purity of scientific method (Perrotta 2012). In other words, 
the scientific images of the bio-object allow us to juxtapose and connect 
scientific views and practices of biomedical research: this means that an-
ticipatory scientific narrations on translational nanomedicine, which is to 
be understood as a science lying on the borderline between the clinical 
world and scientific laboratories, are visualised and translated from a 
merely discursive level to a level of feasibility and scientific manageability. 
 
 
5. The Emergence of Promissory Bio-objects 
 
Scientific research in Onco_N@no identifies a broad process in which 
Martino and Beppe sought to consolidate an experimental procedure for 
the construction of a new biomedical nanotechnology that is capable of 
expressing a set of expectations and visions supporting the possibility of 
translating nanotechnology into patient care devices.  
As mentioned above, this process was implemented within a context 
that extends well beyond the four walls of the laboratory. The technosci-
entific world of Beppe and Martino is populated not only by human ac-
tors “at hand”, but also by objects and technologies of various technical 
complexity that are inherent in scientific practice: Dna (which connects 
the laboratory with the community of molecular biologists), NanoEngi-
neer-1 software (which connects Onco_N@no with the community of 
nanotechnologists), the laboratory journal (which collects all activities 
and data that will be published and made available to the international 
community) and expectations regarding the use of nanodevices (which 
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connect the laboratory with the clinical world). However, when translated 
from the public sphere to the confines of local laboratories, expectations 
and scientific visions of nanomedicine become, principally, technical is-
sues that are addressed through the development of experimental stand-
ardised procedures. 
Through the R&D of Tdo, and the subsequent practices of visualisa-
tion and materialisation, that which is exposed to the scientific communi-
ty is not simply a new life technology, but a broader sequence of events, 
something far more abstract that concerns the configuration of a new bi-
omedical approach to the body and disease: 
 
Research in nanomedicine means speculating on treatments 
that will save you from going to the hospital every day. This is the 
most powerful aspect. I believe that, otherwise, there would not be 
enough added value. I mean, what's the point of replacing a 
treatment with another one, if there is no guarantee of improve-
ment? Therefore, I believe that having something that is not par-
ticularly or overly invasive for the patient is paramount. Our goal 
is not only to increase life expectancy of patients with cancer. 
What we want to achieve here is defeating cancer. (Beppe) 
 
With clarity and conciseness, Beppe emphasises the scientific chal-
lenge undertaken by the director of Onco_N@no: the development and 
testing of nanodevices operating within the body that are capable of rede-
fining the trajectories of patient bio-medicalization. In this sense, the in-
novative content of translational nanomedicine lies not so much in the 
direct manipulation of matter at an atomic level, but in the development 
of techniques and methods for the creation of devices for molecular in-
tervention, or rather the shaping of “programmable”, clinically relevant 
and promising biological entities.  
From a theoretical perspective, Tdo, similar to other nanodevices cre-
ated in biomedical laboratories, is the product of diverse practices for 
understanding and improving human life, namely with the creation of 
tangible objects that can be used in the clinic to govern the development 
of pathological processes (Webster, 2012). These bio-objects also tend to 
blur the conventional boundaries between “human” and “non-human”, 
which are traditionally assumed by life sciences in general (Holmberg et 
al. 2011). The use of Dna as ‘natural’, programmable and bio-compatible 
material allows the location of the bio-object within a hybrid domain that 
exceeds the dichotomy between the natural and artificial character of 
therapeutic intervention.  
One last aspect of particular relevance is associated with the 
knowledge they incorporate. As previously discussed, the practices of 
construction of the bio-object were triggered by the promissory debate on 
a nanomedical future that is populated with a number scientific views and 
expectations regarding the possibility of intervening in therapeutic path-
ways with new nanodevices. More precisely, expectations and future-
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oriented scientific narrations appealed to biomedical experimental activi-
ties, so that the continuous reproduction of their meaning by way of prac-
tical use bestows their material stability and credibility. In this respect, 
the emerging biomedical domain is not generated by biomedical expecta-
tions and anticipatory narrations. The generative dimension lies, instead, 
in the relationship between anticipatory narrations and local experimental 
practices, where the promissory bio-object is a relational and emerging ef-
fect of a contingent technoscientific system that is only partially stable.  
Therefore, the process of Tdo materialisation should not be under-
stood in finalistic terms, as a scientific fact of linear innovation and devel-
opment, but as the local and contingent product of an ecology of actions, 
where expectations and future-oriented biomedical narrations provide a 
resource to support situated practices. At the same time, the images of the 
bio-object represent some type of mediators of sense, allowing the com-
munication and actualisation of anticipatory biomedical narrations. 
Overall, the theoretical juxtaposition of the material and anticipa-
tory/discursive dimensions allows the definition of an analytical space 
that is outlined by the concept of promissory bio-objects. This reveals 
how anticipatory narrations and scientific views shall not remain mere 
discursive representations, but can return a set of images capable of feed-
ing back on the present, directing the actions and intentions of social ac-
tors engaged in the practices of biomedical research.  
The analytical potential of the concept of the promissory bio-object 
lies in the ability to investigate multiple forms of materialisation of expec-
tations and scientific views, which find, in R&D activities and in the ma-
teriality of life technology, the ideal conditions for actualisation. This 
means that expectations are activated as long as they provide an instru-
ment for supporting the local set of contextual elements for the articula-
tion of research practices. Situated practices, in turn, give back credibility 
and materiality to the discursive dimension that forms the basis of antici-
patory statements.  
Finally, this concept reveals how contemporary biomedicine and the 
contextual processes of bio-medicalization are built through a process of 
alignment of different elements (data, laboratory tests, technologies, sci-
entists, doctors and narrations), whereby the practices of translational re-
search in nanomedicine intertwine with anticipatory knowledge, visions 
of the future and visual representations, providing an opportunity to in-
vestigate the relationships that develop between scientific narrations, sit-
uated practices and technologies. 
 
 
6. Final Remarks 
 
In this paper, nanomedicine has been framed as an emerging field in 
the cooperation between human actors and technological devices, scien-
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tific images, linguistic resources and discursive practices, in order to un-
derstand how expectations and scientific narrations can be addressed and 
coordinated within experimental contexts, where biomedical knowledge 
and new therapeutic indications are produced and shared. Indeed, the 
analysis of nanomedicine showed well, as the aspirations and expectations 
take shape in processes in which researchers are pursuing specific objec-
tives, experiencing what is translational nanomedicine, and representing 
it as a concrete possibility. 
With reference to the daily activities for building a nanodevice, I tried 
to show how the future can be considered as a discursive arena densely 
populated with claims, interests, views on medicine and representations 
of bodies and treatments, which are recursively translated into present 
courses of action through the situated practices of biomedical research. 
If, on the one hand, these practices draw on anticipatory visions, on the 
other hand they confer robustness by attempting to generate new tech-
nologies that incorporate planning qualities strongly biased towards the 
future.  
The theoretical perspective outlined in this contribution led to the 
formulation of the notion of promissory bio-objects as a conceptual de-
vice that proves useful for investigating the relationships between the an-
ticipatory narrative level and the materiality of scientific activity. This 
helps to clarify how an emerging biomedical domain, with blurred and 
changing boundaries, is legitimised and made scientifically credible, that 
is, it is capable of generating innovative technologies. Ultimately, promis-
sory bio-objects show a hybrid character that allows joint analysis of hu-
man actors, technologies and anticipatory knowledge, as the fundamental 
and constitutive element of the experimental processes peculiar to con-
temporary biomedical research. Expectations and scientific views are not 
mere cognitive issues, but elements materially embedded in the ongoing 
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